Kristina Mirkovi'

Ms. Kristina Mirkovi'

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KMKristina Mirkovi'
Kristina Mirkovi'
JĐJelena Đoković
Jelena Đoković
IJIvan Jančić
Ivan Jančić
Tanja IlicTanja Ilic
Tanja Ilic
Biljana BufanBiljana Bufan
Biljana Bufan
MSMiroslav Savić
Miroslav Savić
Background/Objectives: GL-II-73 is a positive allosteric modulator that is selective for α5GABAA receptors and has physicochemical properties that favor nanocarrier formulations when parenteral delivery to the central nervous system is desired. Our aim was to develop an optimized nanoemulsion containing GL-II-73 and subsequently test whether this would improve permeation across the blood–brain barrier (BBB) and availability in the brain. Methods: The nanoemulsions were formulated and subjected to detailed physiochemical characterization. The optimized formulation was tested in comparison to a solution of GL-II-73 in the appropriate solvent in an in vitro model of the blood–brain barrier based on human induced pluripotent stem cell-derived microvascular endothelial cells, astrocytes, and pericytes. Plasma and brain exposure to GL-II-73 and its metabolite MP-III-022 was investigated in an in vivo neuropharmacokinetic study in rats exposed to the selected nanoemulsion and the conventional solution formulation. Results: The selected biocompatible nanoemulsion exhibited satisfactory physicochemical properties for parenteral administration, with a Z-ave of 122.0 ± 1.5, PDI of 0.123 ± 0.009 and zeta potential of −40.7 ± 1.5, pH of 5.16 ± 0.04, and adequate stability after one year of storage, and allowed the localization of GL-II-73 in the stabilization layer. The permeability of GL-II-73 through the BBB was twice as high with the selected nanoemulsion as with the solution. The availability of GL-II-73 and MP-III-022 (also a positive allosteric modulator selective for α5GABAA receptors) in the brain was 24% and 61% higher, respectively, after intraperitoneal administration of the nanoemulsion compared to the solution; the former increase was statistically significant. Conclusions: The increased permeability in vitro proved to be a good predictor for the improved availability of GL-II-73 in brain tissue in vivo from the formulation obtained by encapsulation in a nanoemulsion. The putative additive effect of the parent molecule and its metabolite MP-III-022 could lead to enhanced and/or prolonged modulation of α5GABAA receptors in the brain.

11 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TSTijana Stanković
Tijana Stanković
Tanja IlicTanja Ilic
Tanja Ilic
BMBranka Divović Matović
Branka Divović Matović
MPMiloš Petković
Miloš Petković
Vladimir DobričićVladimir Dobričić
Vladimir Dobričić
Snezana SavicSnezana Savic
Snezana Savic
Background/Objectives: The novel pyrazoloquinolinone ligand CW-02-79 shows a unique profile of selective binding to σ2 receptors, but its poor solubility in both water and lipids makes its research and development a burdensome task. We aimed to develop a phospholipid-complex-based nanoemulsion formulation containing CW-02-79 suitable for intravenous administration in preclinical research. Methods: The decorated and undecorated nanoemulsions were formulated and subjected to detailed physiochemical characterization. The delivery and exposure to CW-02-79 from selected nanoemulsions were examined in the in vitro blood–brain barrier model based on human-induced pluripotent stem-cell-derived microvascular endothelial cells, astrocytes, and pericytes, and in vivo neuropharmacokinetic study in rats, respectively. Results: The developed biocompatible nanoemulsions loaded with a CW-02-79—phospholipid complex at a mass ratio of 1:10 exhibited a small droplet size and narrow size distribution, with satisfactory physicochemical stability during steam sterilization and short-term storage at 25 °C. The analysis of protein binding interactions revealed that the PEGylated nanoemulsions had fewer observable interactions compared to the undecorated nanoemulsions, especially when 0.2% DSPE-PEG2000 and 0.1% DSPE-PEG2000-mannose were combined. An in vitro BBB study demonstrated that a substantial part of CW-02-79 present in the applied nanoemulsion is able to permeate the barrier. The quantification of CW-02-79 in plasma/brain homogenate and calculated pharmacokinetic parameters confirmed good systemic and brain availability after intravenous administration. There were subtle differences in the pharmacokinetic parameters in favor of a dual surface-functionalized nanoemulson containing the glucose transporter-1-targeting ligand (mannose). Conclusions: The developed and characterized nanoemulsions enable substantial brain exposure to CW-02-79 as a prerequisite for a pharmacologically and clinically relevant selective modulation of σ2 receptors.

1 January 2025
Verified
Conference Paper
Open access
PDF file
KMKristina Mirkovi'
Kristina Mirkovi'
VTVanja Todorovic
Vanja Todorovic
JIJana Ivanović
Jana Ivanović
JAJovana Aranđelović
Jovana Aranđelović
Diabetes type 2 (T2D) is a very common metabolic disorder strongly associated with poor lifestyle choices and obesity. However, hyperglycemia and impaired insulin signalling not only lead to complications in the periphery but also affect brain function. T2D is one of the main risk factors for the development of dementia, as it suggested, in a sex-dependent manner. In line with this, cognitive impairment has received attention as an emerging complication of T2D in recent scientific literature [1]. Similarly, depression may also co-occur with T2D due to overlapping lifestyle and genetic factors. However, the molecular mechanisms underlying brain changes caused by metabolic imbalance in T2D remain largely unexplored. Furthermore, the antidiabetic drug semaglutide has shown potential in treating cognitive impairment in recent studies [2, 3] suggesting an effect on brain modulation. Thus, we investigated how T2D affects the brain through behavioral testing in a rat T2D model of both sexes. In addition, we have evaluated the effects of semaglutide treatment in this model. Indeed, both cognitive impairment and anhedonia were observed in T2D animals compared to controls, while semaglutide showed promising sex-dependent effects on these conditions. In conclusion, the translationally relevant T2D model, combined with an extensive behavioral test battery, may offer a comprehensive understanding of the disease and the effects of semaglutide on the central nervous system, which could be further linked to potential molecular changes in brain structures caused by T2D.

1 January 2026
Verified
Conference Paper
Open access
PDF file
KMKristina Mirkovi'
Kristina Mirkovi'
JIJ. Ivanović
J. Ivanović
VTVanja Todorovic
Vanja Todorovic
TST. Stanković
T. Stanković
ASA. Santrač
A. Santrač
JAJ. Aranđelović-Ilić
J. Aranđelović-Ilić
Middle-aged women are at a crossroads in terms of their brain health and risk of neurodegenerative disorders, and this vulnerability may be further exacerbated by common metabolic conditions such as diabetes type 2 (T2D). Alzheimer's disease is more prevalent in this population compared with men, and some data also suggest higher prevalence of cognitive decline in females versus males with T2D. Nevertheless, there is limited evidence on the underlying brain molecular mechanisms in females in both clinical and preclinical research, including transcriptomic profiling of the prefrontal cortex (pfc), as brain region involved in cognitive functions. Therefore, we modeled T2D in female rats and performed transcriptomic analysis of the pfc. Middle-aged female Sprague-Dawley rats fed by high-fat diet and treated with low-dose streptozotocin were selected as T2D group, while control group (CTRL) received control diet and was treated by solvent. Bulk RNA sequencing was performed on pfc tissue from the respective experimental groups, followed by quality control, normalization, and differential expression analysis. Pathway enrichment analysis based on KEGG database was then conducted in GeneCodis 4 Web tool. In pfc, the top 10 significantly enriched pathways in T2D females vs CTRL females were to basal transcription factors, pancreatic secretion, aldosterone-regulated sodium reabsorption, mineral absorption, insulin secretion, lysine degradation, thyroid hormone synthesis, carbohydrate digestion and absorption, glycerophospholipid metabolism, and proximal tubule bicarbonate reclamation. These findings suggest that females should not be neglected in research, as our insights implicate hormone-related, electrolyte, and metabolic mechanisms in T2D-associated pfc changes.

1 January 2025 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
ĐĐĐorđe Đorović
Đorđe Đorović
JIJana Ivanović
Jana Ivanović
KMKristina Mirkovi'
Kristina Mirkovi'
DSDishary Sharmin
Dishary Sharmin
JAJovana Arandjelovic
Jovana Arandjelovic
MSMiroslav Savić
Miroslav Savić
Introduction: Depression is a multifaceted disorder with a limited therapeutic repertoire. A significant breakthrough in depression research has been the discovery of fast-acting antidepressants that target the glutamate/GABA system, namely ketamine and neurosteroids. Positive modulation of GABA A receptors containing the a5 subunit (a5GABAARs) represents a promising new approach for targeted therapy of depression. The aim of this study was to investigate the effects of repeated administration of ketamine, an NMDA antagonist, and GL-II-73, a positive allosteric modulator at a5GABAARs, on behavioral despair, anxiety, and locomotor activity. Material and Methods: The experiments were performed on adult male Sprague-Dawley rats. Animals were treated for 7 days with either 6 mg/kg or 10 mg/kg ketamine in an intermittent dosing regimen, 10 mg/kg GL-II-73, or solvent. Following treatment, we performed a battery of behavioral tests consisting of forced swim test (FST), spontaneous locomotor activity (SLA), and novelty suppressed feeding test (NSFT). Results: No change was detected in any of the treatment groups regarding performance in the FST and NSFT. In SLA, all forms of treatment caused a decrease in the percentage of central time at both 10 and 30 minutes. Central distance was reduced at 10 and 30 minutes only after the 10 mg/kg dose of ketamine. Conclusion: Ketamine at the higher dose (10 mg/kg) elicited behavioral changes consistent with a slight increase in emotional reactivity, while minor changes of the same quality in the lower-dose ketamine and GL-II-73 groups hardly reflect any anxiety-inducing influence.

1 January 2025
Verified
Conference Paper
Open access
PDF file
KMKristina Mirkovi'
Kristina Mirkovi'
VTVanja Todorovic
Vanja Todorovic
JIJana Ivanović
Jana Ivanović
JAJovana Aranđelović
Jovana Aranđelović
Spatial memory could be compromised in diabetes type 2 (T2D) patients even at early stages of the disease. In addition, anhedonia can co-occur in T2D patients and negatively impact quality of life. The glucagon-like peptide 1 receptor agonist semaglutide has demonstrated advanced clinical efficacy in glycemic regulation, but recent literature suggests its effects may extend beyond this. This study therefore aimed to assess the effects of semaglutide treatment on spatial memory and anhedonia in type 2 diabetes and obesity model in aging rats of both sexes. After validation of the T2D model, middle-aged Sprague-Dawley rats of both sexes, fed a high-fat diet and treated with streptozotocin, were used. They received either vehicle or semaglutide and underwent an extensive behavioral battery, including the sucrose preference test (SPT) and Morris water maze (MWM). Semaglutide treatment did not affect the latency to reach the platform zone in MWM probe test, but main effect of sex was identified, with females having higher values than males. In T2D females, semaglutide increased sucrose preference compared to vehicle. Semaglutide treatment was associated with increased sucrose preference, which could be relevant for T2D patients experiencing mood changes, and this model may serve for further investigation of underlying mechanisms.